23rd Annual Scientific Meeting of the Australasian Society of Clinical Immunology and Allergy (ASCIA)

5th-7th September 2012
Wellington Town Hall
New Zealand

ASCIA is the peak professional body of clinical immunology and allergy specialists in Australia and New Zealand and is a member society of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology and the World Allergy Organisation

Held in conjunction with:
ASCIA 2012 Allergy and Immunology Update Saturday 8th September 2012
ASCIA 2012 Immunopathology Update Saturday 8th September 2012
ASCIA gratefully acknowledges the generous support of the following sponsors:

**Diamond Sponsors**

- Alphapharm
- CSL Biotherapies
- MSD
- LinkPharma
- Stallergenes

**Platinum Sponsors**

- ALK Abello
- AMSL/allergy
- GSK
- Nestle Nutrition

**Gold Sponsors**

- ABACUS-ALS
- Abbott Nutrition
- Baxter
- Nutricia Advanced Medical Nutrition

**Note: the content of ASCIA 2012 is not influenced by its sponsors or exhibitors**

Sponsors and exhibitors confirmed at the time of publishing this Program Book are as follows:

- Abacus-ALS
- Abbott
- Allergy New Zealand
- Alphapharm
- Allergy and Anaphylaxis Australia
- AusEE
- AMSL/NZMSL/ALK-Abello
- Baxter
- Care Pharmaceuticals
- CSL Biotherapies
- Diagnostic Solutions
- Ego Pharmaceuticals
- ESL Biosciences
- GlaxoSmithKline (GSK)
- HAE Australia
- HAE: Learn About It, Talk About It
- IDFNZ
- Link Medical Products
- MedicAlert
- MSD
- Molnlycke Health Care
- Neilmed
- Nestle Nutrition
- Novartis
- Nutricia Advanced Medical
- Nutricia Baby
- Nycomed - Takeda
- Octapharma
- Shire Australia
- Stallergenes
- Viropharma
On behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA) it is a pleasure to welcome you to the 23rd ASCIA Annual Scientific Meeting, ASCIA 2012, in Wellington New Zealand.

The ASCIA 2012 committee comprising Dr Shannon Brothers, Dr Marianne Empson and Ms Pauline Brown and chaired by Dr Miriam Hurst have worked so hard to bring this conference together, organising a diverse scientific program, covering a wide range of issues in the areas of allergic disease, primary immunodeficiency and systemic autoimmunity.

I look forward to seeing you at ASCIA 2012 and hope you enjoy the fellowship of your ASCIA colleagues and all that Wellington has to offer.

A/Professor Jo Douglass  
ASCIA President

Tēnei te mihi ki a koutou e te manuhiri tūārangi. Greetings to all of our distinguished guests. On behalf of the ASCIA 2012 committee, it is a pleasure to welcome you to ASCIA 2012.

The ASCIA 2012 Annual Scientific Meeting will run for 3 days, from Wednesday 5th to Friday 7th September and will be held in conjunction with:

- ASCIA 2012 Allergy and Immunology Update for health professionals on Saturday 8th September
- ASCIA 2012 Immunopathology Update on Saturday 8th September.

We are honoured to have the following confirmed international keynote speakers for ASCIA 2012:

- Professor Andrew Cant (UK)  
- Professor Carlos Camargo (USA)  
- Dr Jörg Kleine-Tebbe (Germany)  
- Professor Ulrich Wahn (Germany)

ASCIA 2012 also features approximately 50 other speakers and chairs.

The location for ASCIA 2012 is Wellington, New Zealand’s capital city and one of the most picturesque cities, with a stunning harbour surrounded by hills. Wellington is also known as New Zealand’s arts and cultural capital, and its attractions include the waterfront Te Papa Tongarewa Museum, the national museum of New Zealand. Wellington also has a vibrant café scene and some of the best restaurants in the country. We hope that ASCIA 2012 delegates and accompanying visitors will take the opportunity to enjoy the attractions that Wellington and its surrounding areas have to offer.

We are extremely grateful to our:

- Speakers and Chairs for taking time out of their busy schedules to contribute to this meeting
- Sponsors and Exhibitors for their generous support, which enables ASCIA to offer a high quality program whilst keeping the registration fees at a reasonable rate.

We look forward to catching up with you at this meeting.

Dr Miriam Hurst  
ASCIA 2012 Chair
## Program at a Glance

<table>
<thead>
<tr>
<th>Wednesday 5 Sept</th>
<th>Thursday 6 Sept</th>
<th>Friday 7 Sept</th>
<th>Saturday 8 Sept</th>
<th>Saturday 8 Sept</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCIA ASM Day 1</td>
<td>ASCIA ASM Day 2</td>
<td>ASCIA ASM Day 3</td>
<td>Allergy and Immunology Update</td>
<td>Immunopathology Update</td>
</tr>
<tr>
<td>Registration JSAC Breakfast Forum Powhiri (Welcome)</td>
<td>Breakfast Workshop – Diagnostic Dilemmas in PID</td>
<td>Breakfast Session – What’s New in HAE?</td>
<td>ASCIA Nurses Subcommittee Meeting Registration</td>
<td>Registration</td>
</tr>
<tr>
<td>Primary Immune Deficiency (PID) Plenary</td>
<td>Sublingual Immunotherapy Symposium</td>
<td>Food Allergy Plenary</td>
<td>Eczema Symposium</td>
<td>Immune Deficiency Symposium</td>
</tr>
<tr>
<td>Morning Tea</td>
<td>Morning Tea</td>
<td>Morning Tea</td>
<td>Morning Tea</td>
<td>Morning Tea</td>
</tr>
<tr>
<td>Allergy Prevention Symposium</td>
<td>Autoimmunity Symposium</td>
<td>Immune Deficiency Symposium</td>
<td>Primary Immune Deficiency (PID) Symposium</td>
<td>Hypersensitivity Testing Symposium</td>
</tr>
<tr>
<td>Lunch</td>
<td>Lunch</td>
<td>Lunch</td>
<td>Lunch</td>
<td>Lunch</td>
</tr>
<tr>
<td>Clinical Grand Round Oral Presentations</td>
<td>House Dust Mite Research Update ASCIA Resources Update</td>
<td>Anaphylaxis Symposium</td>
<td>Allergic Rhinitis and Allergen Immunotherapy Training</td>
<td>Autoimmunity and QAP Symposium</td>
</tr>
<tr>
<td>Afternoon Tea</td>
<td>Afternoon Tea</td>
<td>Afternoon Tea</td>
<td>Afternoon Tea</td>
<td>Afternoon Tea</td>
</tr>
<tr>
<td>Inflammatory Eye Disease Symposium</td>
<td>Concurrent Poster Discussion Sessions</td>
<td>Vitamin D and Immune System Disorders Symposium ASCIA AGM</td>
<td>Q and A – Allergic Rhinitis And Allergen Immunotherapy Allergy and Immunology Nursing Poster Presentations</td>
<td>Immuno-pathology Poster Presentations</td>
</tr>
<tr>
<td>Welcome Function</td>
<td>ASCIA 2012 Gala Dinner</td>
<td>ASCIA AGM</td>
<td>ASCIA Trainee and Supervisors Dinner</td>
<td>ASCIA Nurses Dinner</td>
</tr>
<tr>
<td>President’s Dinner (International Speakers, ASCIA Executive and ASCIA 2012 Organising Committee)</td>
<td>Infant allergy educational dinner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Secretariat

GPO Box 3270 Sydney NSW 2001
Phone: 02 9254 5000
Fax: 02 9251 3552
Email: registration@ascia2012.com
Website: www.ascia2012.com

## Sponsorship, Exhibition and Program Inquiries

PO Box 450 Balgowlah NSW 2093
Ph: 0425 216 402
Fax: 02 9907 9773
Email: education@allergy.org.au

## ASCIA 2012 Organising Committee

Dr Miriam Hurst (Chair)
Dr Shannon Brothers
Dr Marianne Empson
Ms Pauline Brown (Chair, ASCIA 2012 Allergy and Immunology Update)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00-09.00</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>07.00-08.30</td>
<td>Breakfast Session</td>
<td>JSAC Forum for Advanced Trainees and Supervisors</td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Tiffany Hughes, Dr Melanie Wong, Dr Jan Sinclair, Dr Miriam Hurst</td>
<td>A light breakfast will be served from 07.00-07.30 and is supported by ASCIA. Please note that breakfast cannot be taken into the auditorium.</td>
</tr>
<tr>
<td>08.30-09.00</td>
<td>Powhiri – Official Welcome</td>
<td>Welcome from ASCIA President and ASCIA 2012 Chair</td>
</tr>
<tr>
<td></td>
<td>A/Prof Jo Douglass, Dr Miriam Hurst</td>
<td></td>
</tr>
<tr>
<td>09.00-10.30</td>
<td>Primary Immune Deficiency Plenary</td>
<td>Chairs: Dr Miriam Hurst, Dr Shannon Brothers</td>
</tr>
<tr>
<td>09.00-09.40</td>
<td>Recently identified primary immune deficiency diseases</td>
<td>Prof Andrew Cant</td>
</tr>
<tr>
<td>09.40-10.05</td>
<td>Genetic research studies in a PID cohort</td>
<td>A/Prof Matthew Cook</td>
</tr>
<tr>
<td>10.05-10.30</td>
<td>B cell differentiation: key mechanistic insights gleaned from study of a T cell disorder</td>
<td>Dr Lucinda Berglund</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Morning Tea – Exhibition Area</td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Allergy Prevention Symposium</td>
<td>Chairs: A/Prof Richard Loh, Dr Thorsten Stanley</td>
</tr>
<tr>
<td>11.00-11.45</td>
<td>Allergy prevention: chances and limitations for primary prevention of allergies early in life</td>
<td>Prof Ulrich Wahn</td>
</tr>
<tr>
<td>11.45-12.30</td>
<td>ASCIA 2012 Basten Oration:</td>
<td>A global perspective on allergy: are there targets for prevention?</td>
</tr>
<tr>
<td></td>
<td>A global perspective on allergy: are there targets for prevention?</td>
<td>Prof Innes Asher</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td>Lunch – Exhibition Area</td>
<td></td>
</tr>
<tr>
<td>13.30-15.30</td>
<td>Clinical Grand Rounds – oral presentations</td>
<td>(See page 14 for details)</td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Tiffany Hughes, Dr Sam Mehr</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Afternoon Tea – Exhibition Area</td>
<td></td>
</tr>
<tr>
<td>16.00-17.30</td>
<td>Inflammatory Eye Disease Symposium</td>
<td>Chairs: Dr Marianne Empson, Dr John O’Donnell</td>
</tr>
<tr>
<td>16.00-16.45</td>
<td>An overview of inflammatory eye diseases</td>
<td>Prof Peter McCluskey</td>
</tr>
<tr>
<td>16.45-17.30</td>
<td>Management of inflammatory eye diseases</td>
<td>Prof Denis Wakefield</td>
</tr>
<tr>
<td>17.30-19.30</td>
<td>ASCIA 2012 Welcome Function</td>
<td>Wellington Town Hall West Foyer</td>
</tr>
<tr>
<td></td>
<td>ASCIA 2012 presentations will be held in the Ilott Theatre at the Wellington Town Hall and the ASCIA 2012 exhibition area is in the main auditorium of the Wellington Town Hall.</td>
<td></td>
</tr>
<tr>
<td>19.45</td>
<td>President’s Dinner (for International speakers, ASCIA Executive and ASCIA 2012 Organising Committee) - Museum Art Hotel</td>
<td></td>
</tr>
<tr>
<td>19.45</td>
<td>Infant allergy educational dinner (supported by Nutricia) - Amora Hotel</td>
<td></td>
</tr>
</tbody>
</table>
# Day 2 Program

**Thursday 6 September 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Facilitator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00-08.50</td>
<td><strong>Breakfast Workshop – Diagnostic Dilemmas in Primary Immune Deficiencies</strong></td>
<td>Chair: Prof Andrew Cant&lt;br&gt;Panel: Dr Shannon Brothers, Dr Jane Peake, Dr Miriam Hurst, A/Prof Sean Riminton&lt;br&gt;Breakfast will be served from 07.00-07.30 and is supported by <strong>IDFNZ</strong>&lt;br&gt;Please note that breakfast cannot be taken into the auditorium</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><strong>Sublingual Immunotherapy Symposium</strong></td>
<td>Chairs: Dr Vincent Crump, A/Prof Pete Smith</td>
</tr>
<tr>
<td>09.00-09.45</td>
<td><strong>Mechanisms of sublingual immunotherapy:</strong> new insights and practical implications**</td>
<td>Dr Jörg Kleine-Tebbe</td>
</tr>
<tr>
<td>09.45-10.30</td>
<td><strong>Sublingual immunotherapy with Aero Allergens in Children</strong></td>
<td>Prof Ulrich Wahn</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Morning Tea – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td><strong>Autoimmunity Symposium</strong></td>
<td>Chairs: Dr Stephen Adelstein, Dr Marianne Empson</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td><strong>Biomarkers in SLE:</strong> reinventing the wheel</td>
<td>Dr Stephen Adelstein</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td><strong>Rituximab in the treatment of Vasculitides</strong></td>
<td>Dr Ming-Wei Lin</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td><strong>Pulmonary Hypertension – a multidisciplinary approach</strong></td>
<td>Dr Roger Garsia</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td><strong>Lunch – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>13.30-14.15</td>
<td><strong>House Dust Mite – an international research update</strong></td>
<td>Dr Domingo Barber</td>
</tr>
<tr>
<td>14.15-15.00</td>
<td><strong>ASCIA Education Resources update</strong></td>
<td>A/Prof Richard Loh</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Afternoon Tea – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>15.30-17.00</td>
<td><strong>Concurrent Poster Discussion Sessions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Allergic Diseases</strong></td>
<td>Chairs: Dr Vincent Crump, A/Prof Alyson Kakakios</td>
</tr>
<tr>
<td></td>
<td><strong>Immune Deficiency and Autoimmunity</strong></td>
<td>Chairs: Dr Karuna Keat, Dr Andrew McLean-Tooke</td>
</tr>
<tr>
<td>18.30-23.00</td>
<td><strong>ASCIA 2012 Gala Dinner</strong></td>
<td>Te Papa Museum, Wellington&lt;br&gt;Pre-dinner drinks and tours will be held from 18.30-19.00</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Chair/Presenter</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>07.00-08.50</td>
<td><strong>Breakfast Session – What’s New in HAE?</strong></td>
<td>Prof Connie Katelaris</td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Melanie Wong</td>
<td></td>
</tr>
<tr>
<td></td>
<td>This session is supported by <strong>Shire Australia and Viropharma</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breakfast will be served from 07.00-07.30</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Please note that breakfast cannot be taken into the auditorium</td>
<td></td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><strong>Food Allergy Plenary</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Prof Connie Katelaris, Dr Richard Nolan</td>
<td></td>
</tr>
<tr>
<td>09.00-09.45</td>
<td>Food allergies in children: update in diagnosis and treatment</td>
<td>Prof Ulrich Wahn</td>
</tr>
<tr>
<td>09.45-10.30</td>
<td>Oral immunotherapy and tolerance induction update</td>
<td>A/Prof Mimi Tang</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Morning Tea – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td><strong>Immune Deficiency Symposium</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Miriam Hurst, Dr Melanie Wong</td>
<td></td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Achieving immune reconstitution in primary immunodeficiencies</td>
<td>Prof Andrew Cant</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Immune restoration disease in HIV patients</td>
<td>Prof Martyn French</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>Managing the risks of immunosuppression</td>
<td>A/Prof Sean Riminton</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td><strong>Lunch – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>13.30-15.00</td>
<td><strong>Anaphylaxis Symposium</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Ray Mullins, Dr Jan Sinclair</td>
<td></td>
</tr>
<tr>
<td>13.30-14.05</td>
<td>Jack Jumper Ant vaccine update</td>
<td>A/Prof Bob Heddle, Dr Michael Wiese</td>
</tr>
<tr>
<td>14.05-14.40</td>
<td>Anaphylaxis to anaesthetics</td>
<td>Prof Connie Katelaris</td>
</tr>
<tr>
<td>14.40-15.00</td>
<td>Adrenaline autoinjectors</td>
<td>Dr Marianne Empson</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Afternoon Tea – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>15.30-16.40</td>
<td><strong>Vitamin D and the Immune System Symposium</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Penny Fitzharris, Dr Shannon Brothers</td>
<td></td>
</tr>
<tr>
<td>15.30-16.10</td>
<td>Update on Vitamin D, infection and allergy</td>
<td>Prof Carlos Camargo</td>
</tr>
<tr>
<td>16.10-16.40</td>
<td>An update on Vitamin D research in Australia</td>
<td>Dr Ray Mullins</td>
</tr>
<tr>
<td>16.40-17.30</td>
<td><strong>ASCIA Annual General Meeting</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: A/Prof Jo Douglass</td>
<td></td>
</tr>
<tr>
<td>17.30-18.30</td>
<td><strong>ASCIA 2012 Closing Function</strong> (including wine and cheese)</td>
<td>Wellington Town Hall West Foyer</td>
</tr>
<tr>
<td>19.00</td>
<td><strong>ASCIA Trainee and Supervisors Dinner</strong> (Supported by <strong>CSL Biotherapies</strong>) – Amora Hotel</td>
<td></td>
</tr>
<tr>
<td>19.00</td>
<td><strong>ASCIA Nurses Dinner</strong> (Supported by <strong>Link Pharma</strong> and <strong>Stallergenes</strong>) – Amora Hotel</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Chairs</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>08.30-10.30</td>
<td><strong>Immune Deficiency Symposium</strong></td>
<td>A/Prof Rohan Ameratunga, A/Prof Bill Sewell</td>
</tr>
<tr>
<td>08.30-09.10</td>
<td>Neonatal diagnosis of SCID</td>
<td>Prof Andrew Cant</td>
</tr>
<tr>
<td>09.10-09.50</td>
<td>The role of flow cytometry in PID</td>
<td>A/Prof David Fulcher</td>
</tr>
<tr>
<td>09.50-10.30</td>
<td>Dendritic cell subsets in human tissue</td>
<td>Prof Rod Dunbar</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Morning Tea</strong></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td><strong>Hypersensitivity Testing Symposium</strong></td>
<td>Dr Karl Baumgart, Dr Richard Steele</td>
</tr>
<tr>
<td>11.00-11.45</td>
<td>Successful interpretation of diagnostic methods: novel clues in allergy testing 2012</td>
<td>Dr Jörg Kleine-Tebbe</td>
</tr>
<tr>
<td>11.45-12.30</td>
<td>Coeliac testing – current issues</td>
<td>Dr Richard Steele</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td>13.30-15.00</td>
<td><strong>Autoimmunity and QAP Symposium</strong></td>
<td>Dr Theo de Malmanche, Bob Wilson</td>
</tr>
<tr>
<td>13.30-14.10</td>
<td>Autoantibody testing – current issues</td>
<td>Bob Wilson</td>
</tr>
<tr>
<td>14.10-14.50</td>
<td>RCPA Immunology Quality Assurance Program (QAP) Update</td>
<td>Dr Tiffany Hughes</td>
</tr>
<tr>
<td>14.50-15.00</td>
<td>Question Time</td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Afternoon Tea</strong></td>
<td></td>
</tr>
<tr>
<td>15.30-17.00</td>
<td><strong>Immunopathology poster presentations</strong></td>
<td>Dr Marianne Empson, Dr Miriam Hurst</td>
</tr>
</tbody>
</table>

Saturday 8 September 2012

Immunopathology Update
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00-08.50</td>
<td><strong>ASCIA Nurses subcommittee meeting</strong></td>
<td>Chairs: Pauline Brown, Geraldine Dunne</td>
</tr>
<tr>
<td></td>
<td>A light breakfast will be served from 07.00-07.30</td>
<td></td>
</tr>
<tr>
<td>08.00-09.00</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><strong>Eczema Symposium</strong></td>
<td>Chairs: Pauline Brown, Deryn Thompson</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>PSNZ National Eczema Network Project</td>
<td>Debbie Rickard</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>An overview of atopic eczema in children</td>
<td>Steve Gill</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Management of adult eczema</td>
<td>Deryn Thompson</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Morning Tea – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td><strong>Primary Immune Deficiency (PID) Symposium</strong></td>
<td>Chairs: Janice Capstick, Sacha Palmer</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>An overview of PID</td>
<td>Dr Jan Sinclair</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>SCIG project update</td>
<td>Simone Stephens</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>SCIG paediatric home therapy – an update</td>
<td>Susie Lester</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td><strong>Lunch – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>13.30-15.00</td>
<td><strong>ASCIA Allergic Rhinitis and Immunotherapy training</strong></td>
<td>Chairs: Dr Alison Cunningham, Pamela Burton</td>
</tr>
<tr>
<td></td>
<td>A/Prof Jo Douglass, Dr Sam Mehr</td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Afternoon Tea – Exhibition Area</strong></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Q&amp;A – ASCIA Allergic Rhinitis and Immunotherapy training</td>
<td>Panel: A/Prof Jo Douglass, Dr Sam Mehr, Dr Alison Cunningham, Pamela Burton, Sandra Vale</td>
</tr>
<tr>
<td>16.00-17.00</td>
<td><strong>Allergy and Immunology Nursing Forum – Poster Presentations</strong></td>
<td>Chairs: Pauline Brown, Geraldine Dunne</td>
</tr>
</tbody>
</table>
Professor Andrew Cant  BSc MD FRCP FRCPCH
Consultant in Paediatric Immunology and Infectious Diseases, Newcastle General Hospital
Director, Children’s Bone Marrow Transplant Unit, Great North Children’s Hospital Newcastle
Hon Clinical Professor of Paediatric Immunology, Institute of Cellular Medicine, Newcastle University, UK

Professor Cant has served on the European Society for Paediatric Infectious Diseases (ESPID) education and training committees since 1999, representing ESPID at the Confédération Européenne des Spécialistes en Pédiatrie (CESP), developing Europe wide training programmes in paediatric infectious diseases and immunology that were ratified by the European Medical Union. He was then President of ESPID from 2006 until 2009, and in 2012 was awarded the Bill Marshall award, ESPID’s highest honour.

From 2000 to 2004 he was chairman of the bone marrow transplant working party of the European Society for Immunodeficiencies (ESID); collating and presenting data on Europe wide results of BMT for immunodeficiency and coordinating improved guidelines and protocols. From 2006 until 2010 he was chairman of the ESID educational working party, developing a range of teaching events including the very popular ESID summer school on which he has been a teacher for over 10 years. He has also been involved in supporting the setting up of services for patients with Primary Immunodeficiencies (PID) in Jordan and Malaysia, and reconfiguring and accrediting services in Hong Kong.

In Newcastle he has led a growing research group, active across the fields of Paediatric Immunology, Infectious Diseases and Allergy with significant grant income from MRC, NIHR and others. Since 2000, he has co-authored over 44 publications in the areas of his special expertise that include the natural history and impact of PID, elucidating the causes of hitherto ill understood forms of PID, finding better techniques for BMT in PID, delineating the risk factors in severe and fatal food allergic disease, the detection and better treatment of infection in the immunocompromised and more refined diagnosis of childhood tuberculosis. Professor Cant is a leading expert and pioneer in bone marrow transplantation in children with PID.

Professor Cant’s travel is supported by an educational grant from CSL Biotherapies

Professor Carlos A. Camargo  MD MPH DrPH
Professor of Medicine and Epidemiology, Harvard Medical School and Emergency Physician, Massachusetts General Hospital, Boston USA

Professor Camargo received his MD from the UC San Francisco, MPH from the UC Berkeley and DrPH from the Harvard School of Public Health. His research focuses on respiratory/allergy disorders in several cohorts, including the Nurses’ Health Study. He also founded and directs the Emergency Medicine Network (EMNet, www.emnet-usa.org), a research collaboration involving more than 200 medical centers. EMNet has completed numerous studies on respiratory/allergy emergencies and on other public health issues.

Professor Camargo is past President of the American College of Epidemiology, has worked on several national guidelines including asthma, diet and food allergy and has more than 450 peer reviewed publications.

Dr Jörg Kleine-Tebbe  MD
Allergologist and Dermatologist, Allergy and Asthma Center, Westend, Berlin, Germany

Dr Klein-Tebbe graduated as a medical doctor from the Free University of Berlin in 1986, and in 1988 he was certified as an Allergologist. From 1986 until 1991 he worked as a clinician and researcher at the Asthma Outpatient Department at the Free University of Berlin. This was followed by basic allergy research from 1991 to 1995 as a visiting scientist at the Division of Allergy & Clinical Immunology, at the Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, USA. From 1996 to 2001 he worked at the Allergy Division of the University Dermatology Department, at the University of Leipzig, Germany.

In 2002 Dr Klein-Tebbe became one of the founders of the present Allergy and Asthma Center Westend in Berlin, Germany, a multidisciplinary outpatient clinic with associated clinical research center (allergy, asthma and dermatology). Dr Kleine-Tebbe has lead and co-authored numerous publications and guidelines on allergy, mechanisms in IgE-mediated disorders, diagnostic tests and allergen-specific immunotherapy, gives frequent lectures and is a member of several professional allergy associations.

Dr Kleine-Tebbe’s travel is supported by ALK-Abello.
Professor Wahn became a medical specialist for paediatrics in 1977 and allergology in 1978 at the University Children's Hospital in Heidelberg, Germany. From 1978 to 1979 he held the Fellowship of the Deutsche Forschungsgemeinschaft (DFG) at the National Institutes of Health, Bethesda, Maryland, USA. From 1981 until 1985, he was senior physician and Assistant Professor at the Children’s Hospital Bochum, Germany. Since 1986 he has been Professor for paediatric pneumology and immunology (C3) at the University Children’s Hospital in Berlin, and at the same time Chief Physician of the pediatric department at the HELIOS Hospital Emil von Behring. Since 1998, Professor Wahn has been Director of the clinic for Pediatric Pneumology and Immunology at the Charité, Humboldt University in Berlin, and has also served as Director of the Immunology/Allergology Section of Berlin Laboratory since 2011.

Professor Wahn was President of the European Academy of Allergy and Clinical Immunology (EAACI) from 2003 to 2005 and has been President of several national and international congresses. He has recently been appointed chief editor of the journal “Pediatric Allergy and Immunology”.

His main research interests include the epidemiology of asthma and allergic diseases and the prediction and prevention of allergy. Professor Wahn has published over 400 original papers in peer-reviewed journals and contributed to approximately 30 academic books from different fields of paediatrics, specifically on pneumology, allergology and immunology.

Professor Wahn’s travel is supported by an educational grant from Stallergenes.

ASCIA 2012 Basten Oration
Professor Innes Asher ONZM MBChB FRACP
Professor of Paediatrics: Head of the University of Auckland Department of Paediatrics: Child and Youth Health, and Respiratory Paediatrician, Starship Children’s Health, Auckland, New Zealand

Professor Asher has been the Chair of a worldwide children’s research study for 20 years: the International Study of Asthma and Allergies in Childhood (ISAAC). She co-authored the Global Asthma Report 2011 (http://www.globalasthmareport.org/), produced through collaboration of the ISAAC and The Union. Professor Asher is on the Steering Group of the National Child and Youth Epidemiology Service. She is also on the Management Group of the Child Poverty Action Group NZ. In 2003 Professor Asher was awarded the Officer of the New Zealand Order of Merit for services to Paediatrics, and in 2007 the Health Research Council Liley Medal for her research leadership.
Other Invited Speakers

Steve Gill
Paediatric Dermatology Nurse, Children’s Outpatients Eczema Clinic, Southern District Health Board, Dunedin, New Zealand

A/Prof Bob Heddle
Clinical Immunologist, Allergist and Immunoopathologist, Royal Adelaide Hospital and Chief Pathologist, South Australia
ASCIA Past President

Dr Tiffany Hughes
Clinical Immunologist, Allergist and Immunopathologist, Adelaide, SA Pathology/Royal Adelaide Hospital, South Australia
Chair, RCPA Immunology Quality Assurance Program (QAP)
Chair, RACP/RCPA Joint Specialist Advisory Committee (JSAC) for Training in Clinical Immunology and Allergy

Dr Miriam Hurst
Clinical Immunologist, Allergist and Immunopathologist, Auckland, New Zealand

Prof Connie Katelaris
Head of Unit and Professor of Immunology and Allergy, University of Western Sydney and Campbelltown Hospital, NSW, Australia
President, Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI)
ASCIA Past President

Susie Lester
Paediatric Immunology/Allergy Nurse Specialist, Starship Children’s Health, Auckland, New Zealand

Dr Ming-Wei Lin
Clinical Immunologist, Allergist and Immunopathologist, Westmead Hospital, Sydney, NSW, Australia

A/Prof Richard Loh
Paediatric Clinical Immunologist/Allergist
Head, Dept of Immunology, Princess Margaret Hospital for Children, Perth, Western Australia
Chair, ASCIA Anaphylaxis Working Party
ASCIA President Elect

Prof Peter McCluskey
Director, Save Sight Institute and Professor of Ophthalmology, Sydney Medical School, University of Sydney, NSW, Australia

Dr Sam Mehr
Paediatric Clinical Immunologist/Allergist, Children’s Hospital at Westmead, Sydney, NSW, Australia
Chair, ASCIA Education Committee

Dr Ray Mullins
Clinical Immunologist/Allergist, Canberra, ACT, Australia
ASCIA Past President

Dr Jane Peake
Clinical Immunologist/Allergist, Royal Children’s Hospital, Brisbane, Queensland, Australia
Chair, ASCIA Immunodeficiency Committee

Debbie Rickard
Child Health Nurse Practitioner Candidate, Capital and Coast District Health Board, New Zealand

A/Prof Sean Riminton
Clinical Immunologist, Allergist and Immunopathologist
Department of Immunology and Allergy, Concord Hospital, Sydney, Australia

Dr Jan Sinclair
Paediatric Clinical Immunologist/Allergist, Starship Children’s Hospital, Auckland, New Zealand

Dr Richard Steele
Clinical Immunologist and Immunopathologist, Wellington Hospital, New Zealand

Simone Stephens
Immunology/Allergy Nurse Specialist, Dept of Clinical Immunology, Auckland City Hospital, New Zealand

A/Prof Mimi Tang
Paediatric Clinical Immunologist, Allergist and Immunopathologist
Head, Dept of Allergy and Immunology, Royal Children’s Hospital, Melbourne, Australia

Deryn Thompson
Allergy CN and Eczema Nurse Women’s and Children’s Health Service, Adelaide and Lecturer, University of South Australia

Prof Denis Wakefield
Director, Centre for Immunology and Head of Immunopathology, South Eastern Area Health Service
Associate Dean (Research) and Director of Medical Research, University of NSW, Sydney, Australia

Dr Michael Wiese
School of Pharmacy and Medical Sciences, University of South Australia

Bob Wilson
Supervising Scientist, Autoimmune Laboratory, Division of Immunology, Pathology Queensland
Chair, ASCIA Laboratory Practice Committee
Accommodation

Contact details for the main hotels booked by ASCIA 2012 delegates are as follows:

**Amora Hotel**
www.wellington.amorahotels.com
170 Wakefield Street, Wellington
Tel: +64 4 473 3900
Email: confadmin@wellington.amorahotels.com

**Museum Art Hotel**
www.museumhotel.co.nz
90 Cable Street, Wellington
Tel: +64 4 802 8900, Fax: +64 4 802 8909
Reservations free-phone within NZ: 0800 994 335
Or email info@museumhotel.co.nz

**CQ Hotel (Comfort and Quality Hotels)**
www.hotelwellington.co.nz
223 Cuba Street Te Aro, Wellington
Tel: +64 4 385 2153 (Comfort Hotel) or +64 4 385 2156 (Quality Hotel)
Reservations free-phone: 0800 873 553 (Comfort Hotel) or 0800 888 5 999 (Quality Hotel)
Or email: info@cqwellington.com

Attendance Certificates

Certificates of attendance are included in the registration envelope, together with a receipt for the registration payment for each delegate.

Attractions

Wellington is New Zealand’s capital city and is situated between rolling hills and a stunning harbour. It has a vibrant and compact downtown area that’s best explored on foot. The city is home to Te Papa, the national museum, which tells the story of New Zealand’s history through bold and interactive exhibits. There is also a wide range of cafes, restaurants, art galleries, theatres and nightlife. The gourmet and wine experiences of the Wairarapa region are also just a short drive away. For more information go to:
http://www.wellingtonnz.com/visitor_information
http://www.newzealand.com/au/wellington/

Awards and Travel Scholarships

Several prizes will be awarded, including the best Clinical Grand Rounds Prize ($500), Paul Clarke Allergy Poster Prize ($500), National Asthma Council Poster Prize ($500) and CSL PID Awards ($500 each). Several ASCIA 2012 Travel Scholarships for Advanced Trainees and Medical Students of $500 each will be awarded and successful applicants will be advised at least one month prior to the meeting.

Breakfast Sessions

Breakfast sessions are included in the ASCIA 2012 ASM registration fee. For catering purposes delegates must RSVP for these events upon registration.
Disclaimers
In the event of industrial disruption or a natural disaster the Meeting Organisers cannot be held responsible for any losses incurred by delegates. The program is correct at the time of printing; however the organisers reserve the right to alter the program if necessary.

Dress Code
The dress code is smart casual throughout the Meeting.

Exhibition
We encourage delegates to visit the ASCIA 2012 exhibition stands throughout the Meeting.

Posters and Clinical Grand Rounds
Posters will be on display in the exhibition area on stage, from Wednesday 5th to Saturday 8th September 2012. A list of poster abstracts is included in this Program Book. All ASCIA 2012 poster and Clinical Grand Rounds abstracts have been published online in the Internal Medicine Journal (IMJ).

The URL is available on the ASCIA website:

Poster discussion sessions will be held on the afternoons of Thursday 6th September and Saturday 8th September in the poster area adjacent to the exhibition area. Main authors should attend these sessions.

Clinical Grand Rounds oral presentations will be held on Wednesday 5th September immediately after lunch.

Secretariat
Registration and Abstract submission – ICMS Australasia
GPO Box 3270 Sydney NSW 2001
Level 9, 234 George Street
Sydney NSW 2000 Australia
Phone: 02 9254 5000
Fax: 02 9251 3552
Email: registration@ascia2012.com
Website: www.ascia2012.com

Smoke Free Policy
It is the policy that the ASCIA 2012 Meeting area of the venue and all related social functions are smoke-free.

Social Program
ASCIA 2012 Welcome Function
Wednesday 5th September, 17.30 to 19.30
Wellington Town Hall

President’s Dinner
(for International speakers, ASCIA Executive and ASCIA 2012 Organising Committee)
Wednesday 5th September, 19.45
Museum Art Hotel

Infant Allergy Educational Dinner
(supported by Nutricia)
Wednesday 5th September, 19.45
Amora Hotel

ASCIA 2012 Gala Dinner
Thursday 6th September, 18.30 to 23.00
Te Papa Museum, Wellington

ASCIA 2012 Closing Function
Friday 7th September, 17.30 to 18.30
Wellington Town Hall

ASCIA Trainee and Supervisors Dinner
(Supported by CSL Biotherapies)
Friday 7th September, 19.00
Amora Hotel

ASCIA Nurses Dinner
(Supported by Link Pharma and Stallergenes)
Friday 7th September, 19.00
Amora Hotel

Special Requirements
Please provide details of any special diet, special needs or disability assistance required when you register.

Sponsorship, Exhibition and Program Inquiries
ASCIA Executive Officer
PO Box 450
Balgowlah NSW 2093 Australia
Ph: 0425 216 402 Fax: 02 9907 9773
Email: education@allergy.org.au

Travel
Situated in the centre of New Zealand, Wellington is easily and regularly accessed by plane, train, automobile and ferry. Regular flights to Wellington International Airport are available from most Australian capital cities and it takes approximately 3 hours from Sydney, Melbourne and Brisbane. Wellington International Airport is New Zealand’s domestic airline hub and is just 20 minutes’ drive from the central business district. Transport options to and from the Airport include taxis and airport buses.
All ASCIA 2012 poster and Clinical Grand Rounds abstracts have been published online in the Internal Medicine Journal (IMJ). The URL is available on the ASCIA website:

Clinical Grand Rounds oral presentations will be held on Wednesday 5th September from 13.30-15.30 (immediately after lunch) in the following order:

CGR1  MAS-SIVE CYTOKINE STORM  Dinusha Chandratilleke
CGR2  CONCURRENT DOSING WITH OMALIZUMAB MITIGATES ANAPHYLAXIS DURING ULTRA-RUSH HONEY BEE VENOM IMMUNOTHERAPY IN MONOCLONAL MAST CELL ACTIVATION SYNDROME  Elizabeth da Silva
CGR3  ACQUIRED ANGIOEDEMA WITH RAISED SERUM TRYPHTASE  Jie Shen Fok
CGR4  MANAGEMENT DILEMAS IN A BOY WITH XHIGM  Katie Frith
CGR5  TEETHING OUT THE DIAGNOSIS  Peter Hsu
CGR6  I SMELL A RAT…  Shane Kelly
CGR7  SOMETHING’S NOT RIGHT, I FEEL IT IN MY BONES  Carl Kennedy
CGR8  LESSONS LEARNED: A CASE SERIES REVIEW OF SEVERE ANAPHYLAXIS IN CHILDREN REQUIRING PAEDIATRIC INTENSIVE CARE UNIT (PICU) ADMISSION  Leigh Mackey
CGR9  A CASE OF APECED SYNDROME WITH A B-CELL DIFFERENTIATION DEFECT – EXPANDING THE LINK BETWEEN AUTOIMMUNE DISEASE AND IMMUNODEFICIENCY  Benjamin McGettigan
CGR10  A FETISH FOR FETA ENDED: SEPARATING THE SHEEP FROM THE GOATS!  Babu Philip
CGR11  ADA-DEFICIENT SCID DIAGNOSED AT 3 YEARS OF AGE  Kahn Preece
CGR12  TYPE 1 HYPERSENSITIVITY TO ETHYLENEDIAMINETETRAACETIC ACID  Paul Russo
CGR13  A FATAL IDIOPATHIC SYSTEMIC INFLAMMATORY SYNDROME: NEW OR RARE?  Andrew Whyte
All ASCIA 2012 poster abstracts have been published online in the Internal Medicine Journal (IMJ).

The URL is available on the ASCIA website:

Posters will be on display in the exhibition area on the stage, from Wednesday 5th to Saturday 8th September 2012.

Poster discussion sessions will be held on the afternoons of Thursday 6th September and Saturday 8th September in the poster area adjacent to the exhibition area. Main authors should attend these sessions.

P1 INVOLVEMENT OF THE EYE IN IGG4 RELATED DISEASE: A CASE SERIES  Stephen Adelstein

P2 IDENTIFICATION AND CHARACTERIZATION OF A NOVEL IL-4 RECEPTOR ANTAGONIST FOR ALLERGY TREATMENT  Nayyar Ahmed

P3 THE PREVALENCE OF BRONCHIAL ASTHMA COEXISTING WITH ALLERGIC RHINITIS IN SAUDI ARABIA  Abdulrahman Alfrayh

P4 INCIDENCE, CLINICAL MANIFESTATIONS, AND OUTCOME OF ADVERSE REACTIONS TO INTRAVENOUS RADIO-CONTRAST MEDIA FOLLOWING COMPUTED TOMOGRAPHY (CT)  Yun-Jeong Bae

P5 SKIN TESTING FOR IMMEDIATE HYPERSENSITIVITY TO CORTICOSTEROIDS – A CASE SERIES AND LITERATURE REVIEW  Andrew Baker

P6 CYTOTOXIC T CELL-MEDIATED IMMUNOTHERAPY OF ALLERGIC AIRWAY INFLAMMATION  Naomi Baker

P7 PENICILLIN DE-LABELLING IN TERTIARY CARE CLINICS: SAFE AND EFFICACIOUS BUT INCOMPLETE EFFECTIVENESS?  Jack Bourke

P8 THE DETECTION OF AUTOANTIBODIES TO DOUBLE STRANDED DNA BY RADIOIMMUNOASSAY IN PATIENTS WITH NEGATIVE ANTINUCLEAR ANTIBODIES  Maia Brewerton

P9 SCREENING METHODS FOR NUCLEAR AND CYTOPLASMIC AUTOANTIBODIES – THE DILEMMA OF ASSAY VARIATION  Christine Bundell

P10 MYOSITIS AUTOANTIBODIES DETECTABLE BY IMMUNOBLOTTING OCCUR IN THE GENERAL POPULATION  Christine Bundell

P11 AGE AND GENDER TRENDS IN A CLINICAL COHORT TESTED FOR ANTI NUCLEAR ANTIBODIES  Christine Bundell

P12 SKIN PRICK TEST SENSITISATION PATTERNS AND IMMUNOTHERAPY PRESCRIPTIONS IN GREATER WESTERN SYDNEY  Pamela Burton

P13 TOLERANCE TO WHOLEGRAIN WHEAT CEREAL BISCUIT IN TWO WHEAT-ALLERGIC CHILDREN  Dianne Campbell

P14 BAKED EGG FOOD CHALLENGES – CLINICAL OUTCOMES AND DETERMINATION OF POSITIVE AND NEGATIVE PREDICTIVE VALUES FOR SKIN TESTS TO BAKED EGG AND OVOMUCOID  Dianne Campbell

P15 ROLE OF LYMPHOCYTE SUBSETS IN MONITORING FOR FINGOLIMOD  Patricia Caruana

P16 A MUTATION IN PTPN22 IS ASSOCIATED WITH AUTOIMMUNITY IN PRIMARY ANTIBODY DEFICIENCY  Gary Chew

P17 TH17 CELLS ARE ENRICHED IN RHEUMATOID ARTHRITIS SYNOVIAL FLUID  Kaustav Chowdhury

P18 EXPERIMENTAL HETEROPHYIASIS: HISTOPATHOLOGICAL & IMMUNOLOGICAL STUDY  Ahmed Daoud

P19 NOVEL POLLEN ALLERGENS OF THE SUBTROPICAL JOHNSON GRASS (SORGHUM HALEPENSE) THAT ARE IMPORTANT FOR ALLERGIC RESPIRATORY DISEASE  Janet Davies

P20 CLINICAL HETEROGENEITY IN HEREDITARY ANGIODEMA WITH NORMAL C1-INHIBITOR  Georg Dewald

P21 A SINGLE CENTRE 10 YEARS EXPERIENCE OF MAST CELL DISORDERS  Paul Gatenby

P22 SLEEP AND NEUROCOGNITIVE FUNCTION IN CHILDREN WITH ECZEMA  Michael Gold

P23 ADVERSE EVENTS IN CHILDREN PRESCRIBED NATURAL SALICYLATE ELIMINATION DIETS: A SYDNEY-BASED MULTICENTRE CASE SERIES  Paul Gray
P24 ASSOCIATION BETWEEN EXPRESSION OF TNF-ALPHA IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND ASTHMA Xia Ji
P25 HYDROXYCHLOROQUINE SCREENING BY IMMUNOLOGISTS AND RHEUMATOLOGISTS: KNOWLEDGE AND PRACTICE Connie Katelaris
P26 HEREDITARY ANGIOEDEMA IN AUSTRALIA: PATIENT EXPERIENCE AND BURDEN OF DISEASE Connie Katelaris
P27 IMPROVING CURRENT DIAGNOSTICS AND OUTPATIENT CARE FOR EGG ALLERGIC CHILDREN Monica Kemp
P28 SENSITIZATION TO BLOMIA TROPICALIS IN ALLERGY OUTPATIENTS PRESENTING TO ROYAL BRISBANE AND WOMEN’S HOSPITAL Carl Kennedy
P29 COMPARISON OF ‘DUOTIP II’ LANCET SYSTEM VERSUS METAL LANCETS CURRENTLY IN USE FOR SKIN PRICK TESTING Rosalind Layton
P30 ESTABLISHING A COMBINED IMMUNOLOGY OPHTHALMOLOGY CLINIC Karen Lindsay
P31 ANTI-PHOSPHOLIPASE A2 RECEPTOR ANTIBODIES – AN EVALUATION OF THE CLINICAL UTILITY OF A TRANSFECTED CELL BASED INDIRECT IMMUNOFLUORESCENCE ASSAY IN THE DIAGNOSIS OF IDIOPATHIC MEMBRANOUS NEPHROPATHY Benjamin McGettigan
P32 DOUBLE POSITIVE T CELLS IN A PATIENT WITH GRANULOMATOSIS WITH POLYANGIITIS MaiAnh Nguyen
P33 ASTHMA PHENOTYPE TRIGGERS CORRELATE WITH CLINICAL OUTCOME Efren Rael
P34 THE CONTRIBUTION OF BIRTH ORDER AND PARITY TO THE RISK OF DEVELOPING SYSTEMIC SCLEROSIS Paul Russo
P35 ASCIA ANAPHYLAXIS TRAINING FOR PHARMACISTS Sandra Salter
P36 LEVELS OF SERUM SPECIFIC IGE AND IGG4 AGAINST DER F 2 MITE ALLERGENS IN THAI ALLERGIC PATIENTS Nongmai Sirisomwong
P37 SPHINGOSINE KINASE-1 REGULATES P-SELECTIN EXPRESSION AND NEUTROPHIL RECRUITMENT DURING ALLERGIC INFLAMMATION Wai Sun
P38 EPIDEMIOLOGY OF ADULT ASTHMATICS IN VIETNAM: RESULTS FROM CROSS – SECTIONAL STUDY NATIONWIDE Hanh Tran Thuy
P39 ASCIA ANAPHYLAXIS E-TRAINING TRAINING FOR SCHOOLS AND CHILDCARE: OUTCOMES FROM TWO YEARS OF IMPLEMENTATION Sandra Vale
P40 SPECIFIC IgE DIRECTED AGAINST MAMMALIAN MEAT AND ALPHAGAL IN TICK ANAPHYLAXIS Sheryl Van Nunen
P41 MORADO WOOD-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A VIETNAMESE CARPENTER Sheryl Van Nunen
P42 GUIDING AT-HOME INTRODUCTION OF EGG CONTAINING FOODSTUFFS IN EGG-ALLERGIC CHILDREN BY SKIN TESTING WITH SLURRIES OF EGG-CONTAINING FOODS Sheryl Van Nunen
P43 E-CONSULTATION BETWEEN VIETNAM AND AUSTRALIA: A CONTEMPORARY MODEL FOR REGIONAL COLLABORATION Sheryl Van Nunen
P44 PREDICTION OF SEvere ReACTIONS DURING JACK JUMPER ANT VENOM IMMUNOTHERAPY Andrew Whyte
P45 OCCAM’S RAZOR OR HICKAM’S DICTUM? Andrew Whyte
P46 Ocular lichen planus: an unusual cicatrizng disease Andrew Whyte
P47 OMEGA-5 GLIADIN REACTIVITY IN WHEATDEPENDENT EXERCISE-INDUCED ANAPHYLAXIS Louise Wienholt
P48 THE DIAGNOSTIC UTILITY OF TISSUE TRANSGLUTAMINASE ANTIBODIES IN THE DIAGNOSIS OF COELIAC DISEASE: AN AUSTRALIAN AND NEW ZEALAND PERSPECTIVE OF THE EUROPEAN SOCIETY FOR PAEDIATRIC GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION (ESPGHAN) GUIDELINES Louise Wienholt
### Sponsors and Exhibitors

<table>
<thead>
<tr>
<th>Stand No.</th>
<th>Exhibitor</th>
<th>Wed 5 to Fri 7 Sept 2012</th>
<th>Sat 8 Sept 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,2</td>
<td>Abacus-ALS</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>MedicAlert Foundation</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>Immune Deficiency Foundation NZ</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>Allergy New Zealand</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>Allergy and Anaphylaxis Australia</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>AusEE</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>Ego Pharmaceuticals</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Diagnostic Solutions</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>GSK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>ESL Biosciences</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>Nutricia Baby</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11,12</td>
<td>Nutricia Medical</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Novartis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Nycomed-Takeda</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>15</td>
<td>AMSL/NZMSL/ ALK-Abello</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>16</td>
<td>Abbott Nutrition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Care Pharmaceuticals</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>17</td>
<td>Molnycke Health Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Neilmed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Octapharma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Nestle Nutrition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21,26</td>
<td>MSD</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>22, 23</td>
<td>Baxter</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>24,25</td>
<td>Alphapharm</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>27</td>
<td>Stallergenes</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>32</td>
<td>Link Medical Products</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>28,29</td>
<td>CSL Biotherapies</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>30</td>
<td>HAE: Learn About It, Talk About It</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>31</td>
<td>HAE Australia</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
Abacus-ALS
www.abacus-als.com

Abacus ALS will showcase a number of new advances in allergy, asthma and autoimmunity at ASCIA 2012. We are pleased to have Kerstin Wall (Scientific Advisor, Thermo Fisher Scientific) attend ASCIA this year and would like to invite you to our booth to discuss the latest allergen components. Molecular Allergology can help with risk assessment of the allergy, explain symptoms due to cross-reactivity and help in identifying patients suitable for SIT treatment, supporting the doctor in patient management. The new milk components help identify the patients at risk of having severe reactions, developing tolerance or having risk of concomitant beef allergy.

Another recently introduced test is the EliA Calprotectin assay (the first fully automated Calprotectin stool test available on the Phadia® platforms). EliA Calprotectin can also be run together with a broad panel of other EliA tests used for differential diagnosis of gastrointestinal disorders.

We will also provide you with a complimentary copy of the most up-to-date allergy and autoimmunity resources on a USB stick.

Abbott
www.abbottnutrition.com.au

Abbott Nutrition, a division of Abbott Australasia is committed to advancing patient care by developing innovative solutions in nutritional products. Our leading-edge science is behind some of the world’s most trusted names in medical nutrition, including EleCare®, which is a nutritionally complete amino acid based formula with 1/3 of fat as Medium Chain Triglycerides (MCTs), to aid fat absorption. This product has been specially formulated for infants and children who have multiple food allergies, including cow’s milk protein allergy. In addition, EleCare Unflavoured and EleCare Vanilla are also indicated for the treatment of Eosinophilic Oesophagitis. EleCare® is PBS listed and is available in three variants, EleCare Unflavoured, EleCare Unflavoured with LCP and EleCare Vanilla.

Allergy and Anaphylaxis Australia (AAA)
www.allergyfacts.org.au

Allergy and Anaphylaxis Australia (AAA) is a national, non-profit community support organisation established in 1993 to support and assist those affected by allergy and anaphylaxis. Allergy and Anaphylaxis Australia is dedicated to assisting individuals and their carers in the management of allergic disease including the risk of anaphylaxis. Our aim is to improve the quality of life of those affected by allergy whilst minimising risk to their health and well-being. The organisation advocates for people living with allergies when communicating with government, health and teaching professionals, food industry and the broader community.

Allergy and Anaphylaxis Australia strives to raise awareness of allergy in the Australian community and provides evidence-based information, resources and services to support those with allergy and those who live with the risk of anaphylaxis.

For more information on allergy and anaphylaxis please visit www.allergyfacts.org.au or call 1300 728 000.

Allergy New Zealand
www.allergy.org.nz

Allergy New Zealand Inc is the national patient support organisation in New Zealand. With the support of a Medical Panel (all members of ASCIA) we work to raise awareness and provide evidence-based information and education on all allergies, and support through a national volunteer network to families with children with food allergy. Our quarterly magazine, Allergy Today, is distributed to over 5,000 health professionals. We also represent the interests of the allergic population through submissions and participation in working groups; and are involved in research into the burden of food allergy in New Zealand. See our website for more information.

Alphapharm
www.alphapharm.com.au

Alphapharm is Australia’s leading supplier by volume of prescription medicines to the Pharmaceutical Benefits Scheme (PBS). One in seven prescriptions for PBS medicines is dispensed with an Alphapharm product. Our specialty is bringing generic medicines to market, which contributes to the sustainability of the PBS by providing timely access to quality, safe, efficacious and affordable medicines. Alphapharm medicines are made to the highest global quality standards and have the same effect on the body as initial brands.

Alphapharm pioneered generic medicines in Australia in 1982, with 12 staff and four products. Today, we have around 700 employees nationally, including 500 at our state-of-the-art manufacturing plant at Carole Park, Queensland. This year, the plant will produce 3.5 billion doses of which about 1.7 billion will be exported to some 50 countries around the world. Alphapharm is part of US-based Mylan.

AusEE
www.ausee.org

The Australian Support Network For Eosinophilic Oesophagitis and Related Disorders (ausEE Inc.) is a registered Australian charity and non-profit organisation dedicated to providing support and information to anyone diagnosed with or caring for someone with an Eosinophilic Gastrointestinal Disorder (EGID)
including Eosinophilic oEsophagitis (EoE).

ausEE’s mission is to improve the lives of those affected by providing support and information not only to those with an EGID, but to the greater medical community.

ausEE Inc. currently campaigns and raises funds for further research in Australia. The ausEE website has valuable information and resources including a forum for members. For more information, please visit www.aussee.org

**AMSL / NZMSL / ALK-Abello**

**Australia:** www.amsl.com.au

**New Zealand:** www.nzms.co.nz

At Australasian Medical and Scientific Ltd (AMSL) and New Zealand Medical and Scientific Ltd (NZMS) we deliver leading allergy solutions to allergists, dermatologists and other medical practitioners throughout Australia and New Zealand. Our range includes Sub Lingual, Subcutaneous and Tablet Immunotherapy Vaccines; Skin Prick Test allergens; ready to use and open type Patch Test Systems; intradermal allergy tests for penicillin, amoxicillin and clavulanic acid; RhinoLight for treatment of allergic rhinitis; lancets and accessories. Our range includes leading brands such as ALK Abello, SmartPractice, Lincoln Diagnostics and Diater. We pride ourselves on our experience and expertise in the field of allergy diagnosis and immunotherapy as well as our reliable and excellent service.

For more information please visit www.amsl.com.au (Australia) or www.nzms.co.nz (New Zealand).

**Baxter**

www.baxterhealthcare.com.au

Baxter Healthcare develops, manufactures and markets products that save and sustain the lives of people with haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

**Care Pharmaceuticals**

www.carepharma.com.au

Care Pharmaceuticals (formerly Paedpharm Pty Ltd) was established in Australia in 1986 to provide innovative over the counter products for all members of the family. Their trusted brands including the range of FESS® Nasal sprays are synonymous with quality, safety and efficacy. Whether it’s mild to moderate nasal congestion or severe congestion due to sinusitis, rhinitis and allergies, there’s a FESS® product to help provide relief and help maintain nasal health. All FESS® products are non-medicated so they can be used as often as needed even if pregnant, breastfeeding or on medication. For further information and details on our new products please visit www.carepharma.com.au

**CSL Biotherapies**

www.csl.com.au

CSL has been the chosen national plasma fractionator of Australia since 1953, and New Zealand since 1963. Today CSL Biotherapies works with Australian Governments, the Australian Red Cross Blood Service and the New Zealand Blood Service to deliver a world class and broad range of plasma-derived therapies specifically designed to meet the needs of healthcare professionals and patients in both these countries. CSL Biotherapies, through its research and development program, is committed to ensuring continued world class standards of quality, product yields, patient convenience and manufacturing efficiency in our broad portfolio of plasma-derived therapies. An example of this commitment is the use of modern manufacturing technologies for our products, such as large scale chromatography and the inclusion of at least two dedicated and complementary pathogen reduction steps in the manufacturing process of each product for Australia and New Zealand.

**Diagnostic Solutions**

www.diagnosticsolutions.com.au

Diagnostic Solutions is a leading distributor of high quality, innovative automated systems for autoimmune diagnostic testing across Australia and New Zealand.

The Diagnostic Solutions DSR™ Systems are a new range of automated platforms specifically designed for laboratories that need flexibility combined with high performance. The Image Navigator™ from Immuno Concepts is the most advanced automated IFA system today. With true sample traceability, fast positive / negative screening combined with interfacing to the CARIS™/DSR™ Systems come and talk to us about how we can help your laboratory today.

Australia: 1300 788 003 New Zealand: 0800 448 018

**Ego Pharmaceuticals**

www.egopharm.com

Ego Pharmaceuticals is an Australian family owned and operated company who for more than 50 years have specialised in the manufacture of quality skincare products such as market leaders ‘QV’, ‘Sunsense’, ‘Pinetarsol’, ‘DermAid’ and ‘Moov’. The QV range of gentle moisturisers and cleansers has been scientifically formulated for those who suffer from dry or sensitive skin conditions. The entire QV range is free from colour, fragrance, propylene glycol, lanolin and its derivatives making it ideal for the most sensitive skin types.
ESL Biosciences

www.eslbioscience.com

ESL Biosciences supply high quality, automated in-vitro diagnostic instruments and reagents and provide full training in their use throughout Australasia. With over 25 years of experience in the niche field of autoimmunity we offer a comprehensive range of products from Euroimmun, a world-leader in autoimmune diagnostics. Assays include (but are not limited to) those for Rheumatology, Autoimmune Hepatitis, PBC and Vasculitis. Others include test kits for the determination of Gluten sensitivity, antibody test kits for Autoimmune Mediated Diabetes markers and Autoantibodies in Paraneoplastic Neurological Syndromes (PNS).

ESL Biosciences also presents a range of automated systems to the laboratory.

GlaxoSmithKline (GSK)

www.gsk.com.au

GlaxoSmithKline is a global research-based pharmaceutical and healthcare company with a mission to improve the quality of human life by enabling people to do more, feel better and live longer.

In Australia we have improved people’s wellbeing by delivering the highest quality medicines, vaccines and over-the-counter healthcare products since 1886.

We provide about 1600 skilled jobs across the country, working with researchers and doctors to discover new ways of treating and preventing disease. We invest $58 million a year in local research and development, and supply $477m million to Australia’s pharmaceutical and medicinal exports.

HAE Australia

www.haeaustralia.org.au

HAE Australia is a new not for profit organization, founded by HAE patients and caregivers and is dedicated to providing a support network for those with Hereditary Angioedema (HAE).

HAE Australia is enhancing the support and quality of life for HAE patients, providing education to patients, carers and health care providers and is raising awareness of HAE in the medical and general community, assisting research organizations with their studies into causes, prevention and treatment of HAE. HAE Australia is also looking at ways to make treatment and medications more accessible for patients across Australia.

HAE: Learn About It, Talk About It

www.letstalkHAE.com

Hereditary angioedema (HAE) is a rare, potentially life-threatening swelling condition, commonly misdiagnosed because symptoms are non-specific and often mimic other disorders. HAE: Learn About It, Talk About It™ is a peer-to-peer clinician education programme created to help improve diagnosis of HAE. Partners include American College of Allergy, Asthma and Immunology (ACAAI), American Gastroenterological Association (AGA) Institute, World Allergy Organization (WAO), American College of Emergency Physicians (ACEP), American Academy of Nurse Practitioners (AANP), Society of Emergency Medicine Physician Assistants (SEMPA) and European Academy of Allergy and Clinical Immunology (EAACI). The programme is supported by ViroPharma Incorporated. Visit letstalkHAE.com for more information.

IDFNZ

www.idfnz.org.nz

Immune Deficiencies Foundation of New Zealand (IDFNZ) is a non-profit organization, formed in 1987, which is dedicated to supporting children, teenagers and adults with diagnosed Primary Immune Deficiency (PID) disorders, ongoing medical and scientific research, advocating for patients and educating the public and health professionals about PID. IDFNZ is governed by an Executive Board including two leading medical professionals specialising in PID disorders, has medical and scientific subcommittees and is a member of the International Patient Organisation for Primary Immune Deficiencies (IPOPI).

Link Medical Products Pty Ltd

www.linkhealthcare.com.au

LINK Healthcare is a privately owned Australian-based specialist pharmaceutical and medical technologies business. LINK’s mission is to strive for excellence in the marketing of a vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia and New Zealand.

LINK provides exceptional sales and marketing infrastructure and is partnered with major pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio.

LINK Pharma has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anesthesia, Anti-infective, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.

At ASCIA 2012, Link alongside their partner, Stallergenes, focus...
on the provision of allergy care covering all aspects, from diagnosis to the treatment of anaphylaxis.

**MedicAlert Foundation**

**New Zealand:** [www.medicalert.co.nz](http://www.medicalert.co.nz)

**Australia:** [www.medicalert.com.au](http://www.medicalert.com.au)

Protecting people around the world in times of critical medical need is what MedicAlert Foundation International has been doing for over 50 years. For those who need to convey important and sometimes life-saving information immediately, the MedicAlert medical ID is always there for young and old, day or night, every day of the year. The well recognised and trusted emblem, backed-up with immediate access to important medical and other information is the simplest and most effective way to help protect one's health and well-being. Visit us in the Exhibition Hall for more information.

**Molnlycke Health Care**


Molnlycke Health Care is a world leading manufacture of single-use surgical and wound care solutions for the professional health care sector. The Wound Care Division develops and manufactures products for chronic and surgical wounds burns and complementary products in compression therapy and dermatology. Molnlycke’s unique dressings with Safetac® technology are proven to minimise pain and trauma at dressing change and improve the quality of care, optimise the healing environment and in turn reduce the length of hospital stay or after care treatment. The company also offers a comprehensive range of conventional wound care products, making Molnlycke a one-stop-shop for wound care professionals. Key brands include Mepilex®, Meptiel®, Mepore®, Mefix®, Tubifast® and Tubigrip®. Molnlycke Health Care, Inspiring Confidence.

T: 1800 005 231 F: 1800 005 232
E: csc.au@molnlycke.com

**MSD**


Today’s MSD is a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well. For more information, visit our website.

**Neilmed**

[www.neilmed.com](http://www.neilmed.com)

NeilMed Pharmaceuticals manufacture allergy and sinus relief products. NeilMed’s Sinus Rinse Kit is a soothing saline nasal irrigation system that includes 60 packets of preservative free, isotonic, pH balanced mixture, irrigation bottle and custom designed cap. It has been proven to be highly effective for rhinosinusitis, allergies, and most beneficial for post FESS patients. Phone: 1800 158 900

**Nestle Nutrition**


[www.nestlebaby.co.nz](http://www.nestlebaby.co.nz)

Nestlé Nutrition is the global leader in infant nutrition. Through integrating scientific and research expertise, Nestle Nutrition aims to launch the most innovative, cutting edge products and services to stay at the forefront of nutrition science and technology. As a long time partner of ASCIA please come and visit us at stand 20 during this year’s meeting to find out more about our hydrolysed infant product range.

**Novartis**


Novartis is a world leader in the research, development and supply of medicines to prevent and cure disease, ease suffering and enhance quality of life. Headquartered in Basel, Switzerland, we operate in over 140 countries and employ approximately 100,000 people. Our medicines treat some of the most serious conditions confronting healthcare professionals and patients in the areas of cardiovascular disease, oncology, immunology, infectious diseases and ophthalmics.

**Nutricia**


Nutricia invests in ongoing scientific research to understand the nutritional composition and benefits of breast milk. This learning is applied to our products through a translational research model to help ensure our APTAMIL infant formula products deliver clinically validated nutrition-related health outcomes to infants when exclusive breast milk isn’t available.

Nutrition during early life provides an important foundation for later health. Nutricia has developed an education platform called ‘The Learning Network’ which is facilitated by independent experts to share evidence based and practical paediatric nutrition education. Nutricia also offers a website specifically for Health Professionals called [www.nutricia4professionals.com.au](http://www.nutricia4professionals.com.au). Visit us to find out more.
Neocate - Nutricia Advanced Medical Nutrition

Neocate is a range of world leading amino acid based formulas. These formulas are suitable for the dietary management of cow’s milk allergy, multiple food protein allergies and other conditions that require an elemental formula in infants and children. No other amino acid formula is clinically proven to be effective across a broad range of food allergy associated conditions. We have recently launched Neocate Gold and Neocate Advance (vanilla), and we look forward to discussing with you how these recent additions to our range offer an unmatched superior nutritional profile, so your patients can conquer allergy and thrive.

Nycomed-Takeda

www.nycomed.com/au/takeda

Takeda is a research-based global pharmaceutical company. It is the largest pharmaceutical company in Japan and one of the global leaders of the industry.

Setting our management philosophy, “Takeda-ism” as the basis of business, Takeda is committed to striving towards better health for patients worldwide through leading innovation in medicine. Takeda’s in-house ethical drugs are marketed in around 90 countries worldwide and are recognized as the brand in major countries worldwide.

Takeda Pharmaceuticals Australia focuses on the respiratory, gastrointestinal, oncology and diabetes therapeutic areas.

Octapharma

www.octapharma.com.au

Octapharma specialises in the development and production of human proteins derived from plasma and recombinant technologies. Using cutting-edge purification and viral inactivation techniques we live by our mission of “for the safe and optimal use of human proteins.” We work to the highest standards of quality and safety required by physicians, patients and regulatory authorities globally.

Since 2005 Octapharma Australia has supplied Octagam® 5% IVIG (Human Normal Immunoglobulin, IV Solution) for Australian patients, and now the Octagam®10% IVIG. These products offer choice and flexibility for physicians; offering an ideal product for every patient. Please contact Octapharma Australia for more information.

Shire Australia

www.shireaustralia.com.au

As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Since opening its doors in May 2008, Shire Australia has registered products for use in rare genetic diseases such as Fabry Disease and Hereditary Angioedema and in specialty pharmaceuticals in the areas of Hyperphosphataemia in chronic Renal Disease, Essential Thrombocythaemia and mild to moderate active Ulcerative Collitis.

Customer Services: 1800 012 612 or email: enquiriesaustralia@shire.com

Stallergenes

www.stallergenes.com

Based on 50 years of experience, Stallergenes, a biopharmaceutical company, has been and continues to be a leader and pioneer in allergen immunotherapy. Devoting about 20% of its turnover to R&D each year, Stallergenes continues to enhance its commitment to develop innovative and evidence based treatments. The company has recently obtained marketing approval for Oralair, the grass pollen sublingual tablet, in both NZ and Australia.

Stallergenes ANZ and LinkPharma combine their efforts to improve allergy care in Australasia, strengthening their commitment to become the key partner of allergy specialists by providing the only registered treatments on the ANZ market: diagnostics (Holister-Stier), subcutaneous treatments (Alustal and Albey) and sublingual tablet (Oralair) together with sublingual drops as Named Patient Products. Stallergenes products are distributed by EBOS Healthcare in New Zealand.

Viropharma

www.viropharma.com

ViroPharma Inc has provided an unrestricted education grant for ASCIA 2012 and also to HAEi (HAE International).

ViroPharma Inc is an international biopharmaceutical company committed to developing and commercialising innovative products that address unmet medical needs, including diseases caused by C1 esterase inhibitor deficiency and C. difficile.

ViroPharma Inc is represented in Australia by Cedarglen Investments Pty Ltd, a consulting company providing services to international biotechnology companies, enabling Australian patients to benefit from innovative therapies. Services include product registration, funding, marketing and sales of life-saving products for ultra-Orphan diseases. For further information please contact:

Paul.Finnegan@viropharma.com
Davidclewisoz@gmail.com
Meddygol@me.com
<table>
<thead>
<tr>
<th>Year</th>
<th>ASCIA ASM</th>
<th>Location</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>1990</td>
<td>1st ASCIA ASM</td>
<td>Melbourne VIC (Hilton on the Park)</td>
<td>April 29 - May 1</td>
</tr>
<tr>
<td>1991</td>
<td>2nd ASCIA ASM</td>
<td>Perth, WA (Burswood Hotel)</td>
<td>December 1-3</td>
</tr>
<tr>
<td>1992</td>
<td>3rd ASCIA ASM</td>
<td>Cairns, QLD (Hilton Hotel)</td>
<td>September 13-15</td>
</tr>
<tr>
<td>1993</td>
<td>4th ASCIA ASM</td>
<td>Sydney, NSW (Darling Harbour)</td>
<td>April 29 - May 1</td>
</tr>
<tr>
<td>1994</td>
<td>5th ASCIA ASM</td>
<td>Canberra, ACT (Lakeside Hotel)</td>
<td>December 2-5</td>
</tr>
<tr>
<td>1995</td>
<td>6th ASCIA ASM</td>
<td>Sydney, NSW (Regent Hotel)</td>
<td>October 30-November 3 with TPAIS</td>
</tr>
<tr>
<td>1996</td>
<td>7th ASCIA ASM</td>
<td>Adelaide, SA (Hyatt Hotel)</td>
<td>December 5-7</td>
</tr>
<tr>
<td>1997</td>
<td>8th ASCIA ASM</td>
<td>Wellington, NZ (Convention Centre)</td>
<td>April 5-8 with TSANZ</td>
</tr>
<tr>
<td>1998</td>
<td>9th ASCIA ASM</td>
<td>Brisbane, QLD (Sheraton Hotel)</td>
<td>August 28-30</td>
</tr>
<tr>
<td>1999</td>
<td>10th ASCIA ASM</td>
<td>Uluru, NT (Ayers Rock Resort)</td>
<td>September 24-27</td>
</tr>
<tr>
<td>2000</td>
<td>11th ASCIA ASM</td>
<td>Sydney, NSW (Convention Centre)</td>
<td>October 15-20</td>
</tr>
<tr>
<td>2001</td>
<td>12th ASCIA ASM</td>
<td>Perth, WA (Sheraton Hotel)</td>
<td>September 28-30</td>
</tr>
<tr>
<td>2002</td>
<td>13th ASCIA ASM</td>
<td>Adelaide, SA (Hilton Hotel)</td>
<td>September 27-29</td>
</tr>
<tr>
<td>2003</td>
<td>14th ASCIA ASM</td>
<td>Melbourne, VIC (Sheraton Southgate Hotel)</td>
<td>September 10-12</td>
</tr>
<tr>
<td>2004</td>
<td>15th ASCIA ASM</td>
<td>Gold Coast, QLD (Marriott Hotel)</td>
<td>September 8-10</td>
</tr>
<tr>
<td>2005</td>
<td>16th ASCIA ASM</td>
<td>Queenstown, NZ (Millennium Hotel)</td>
<td>August 31 - September 2</td>
</tr>
<tr>
<td>2006</td>
<td>17th ASCIA ASM</td>
<td>Sydney, NSW (Manly Pacific Hotel)</td>
<td>September 7-9</td>
</tr>
<tr>
<td>2007</td>
<td>18th ASCIA ASM</td>
<td>Fremantle, WA (Esplanade Hotel)</td>
<td>November 14-16</td>
</tr>
<tr>
<td>2008</td>
<td>19th ASCIA ASM</td>
<td>Melbourne (Park Hyatt Hotel)</td>
<td>November 12-14</td>
</tr>
<tr>
<td>2009</td>
<td>20th ASCIA ASM</td>
<td>Adelaide, SA (Adelaide Convention Centre)</td>
<td>September 16-18</td>
</tr>
<tr>
<td>2010</td>
<td>21st ASCIA ASM</td>
<td>Gold Coast, QLD (Gold Coast Convention &amp; Exhibition Centre)</td>
<td>September 1-4</td>
</tr>
<tr>
<td>2011</td>
<td>22nd ASCIA ASM</td>
<td>Sydney, NSW (Sydney Convention &amp; Exhibition Centre)</td>
<td>Darling Harbour, September 6-10</td>
</tr>
<tr>
<td>2012</td>
<td>23rd ASCIA ASM</td>
<td>Wellington, New Zealand (Wellington Town Hall)</td>
<td>September 5-7</td>
</tr>
</tbody>
</table>

23 years of ASCIA Annual Scientific Meetings 1990 – 2012

www.allergy.org.au